Home -> Law Blog Directory -> Patent Law Blogs -> Patently Obvious
(866) 635-2689 for Personal Injury or (866) 635-9402 for Criminal Defense
Find a Local Lawyer
Divorce (866) 635-6190
Personal Injury (866) 635-2689
Criminal Defense (866) 635-9402
Patent Law
: Patently ObviousThe BPAI's Standard of Review for Examiner Rejections
By Dennis Crouch, Esq.
Ex Parte Frye (BPAI 2010) (precedential opinion)
In a newly issued precedential opinion, the Board of Patent Appeals and Interferences (BPAI) has ruled that examiner findings are given no deference when challenged on appeal.
"[T]he Board reviews the particular finding(s) contested by an appellant anew in light of all the evidence and argument on that issue.'
However, examiner findings that are not specifically challenged will not normally be disturbed by the BPAI.
"If an appellant fails to present arguments on a particular issue – or, more broadly, on a particular rejection – the Board will not, as a general matter, unilaterally review those uncontested aspects of the rejection. . . . For example, if an appellant contests an obviousness rejection only on the basis that a cited reference fails to disclose a particular limitation, the Board need not review the other, uncontested findings of fact made by the examiner underlying the rejection, such as the presence of uncontested limitations in the prior art."
The BPAI opinion is also notable because its signatories include the USPTO Director (Kappos) and Deputy Director (Barner). Although it is unusual for the PTO director to take part in BPAI decisions, the Director is a statutory member of the BPAI under 35 U.S.C. 6(a). Based on the 2008 "Duffy amendments" to Section 6, the Deputy Director apparently now has the same status. I say "apparently" because Westlaw claims that the amendment was technically deficient.
Director Kappos has written a blog post about the opinion.
Full post as published by Patently Obvious on March 11, 2010 (boomark / email).
FDA Issues Update on Safety Review Orlistat
Orlistat FDA Issues Update on Safety Review
Aurora Loan Faces Class Action over Mortgage Review Services
Aurora Loan Faces Class Action over Mortgage Review Services
FDA Review of Prostate Cancer Treatment Prompts Warning of Risk for Diabetes
Prostate Cancer Treatment FDA Review Prompts Warning of Risk for Diabetes
Xigris
Study Prompts FDA Safety Review
Lipitor
Review of Studies Show No Significant Benefit in Women
Wrinkle-Fillers
FDA to Review Labeling due to Adverse Event Reports

A First Glance at the Proposed New BPAI Rules
Official Notice and Tips for Responding to Rejections Based on Official Notice
Just-n-examiner on apologies and 35 USC 101
A FEW WAYS TO GET ON THE BAD SIDE OF YOUR EXAMINER








